The global geographic distribution of HBV genotypes, mutations and associated CpG promoter DNA methylation.
Worldwide, it is estimated that more than 400 million people are currently living with chronic hepatitis B virus (HBV) infection, contributing to more than one million deaths annually as a result of liver cirrhosis and hepatocellular carcinoma (HCC). HBV DNA integrates into the cellular DNA in liver tissue of patients with chronic HBV infection and HCC. Following HBV infection, DNA methyltransferases (DNMTs) methylate any HBV DNA integrated into the human genome. This novel epigenetic mechanism enables the suppression of HBV antigens, leading to reduced viral replication. HBV is thought to induce DNA methylation via hepatitis B x (HBx) protein, which modulates cellular signalling pathways by activating DNMT 1 and 3 to benefit the virus. Activation of DNMT 1 and 3 inappropriately methylates host cellular genes including tumour suppressor genes whose disruption causes transformation of hepatocytes and hepatic malignancy. By being localised in the cytoplasm, nucleus and mitochondria of HBV-infected hepatocytes, it appears that HBx protein manages to exploit the entire body of cellular signalling pathways for viral survival and propagation. HBx protein may achieve its transcriptional transactivation action by either interacting with key genes or altering their related cellular signalling pathways or by hijacking their binding partners and taking over their roles. Although the underlying mechanisms are still unclear, processes such as cell cycle progression, calcium homeostasis, hepatic metabolism, protein ubiquitination, RNA splicing and vitamin D receptor regulation are key mechanisms that HBx protein alters to favour viral replication and cell survival. These detrimental effects would connect HBV infection to malignant transformation by inducing uncontrolled cell growth, proliferation and disrupting apoptosis.
- epigenetics alterations
- viral integration
- hepatitis B virus
- hepatocellular carcinoma
- hepatitis X antigen
1. Hepatitis B virus
Hepatitis B virus (HBV) is one of the most prevalent infections in humans and important cause of acute and chronic hepatitis. Chronic infection is defined as the presence of hepatitis B surface antigen (HBsAg) in the blood more than 6 months following initial infection. Without treatment, chronic HBV infection may result in the development of liver cirrhosis and hepatocellular carcinoma (HCC) [1–3].
HBV was first identified in the 1960s and was the first human hepatitis virus to be well characterised at a molecular level [3, 4]. Long-term inflammatory changes due to chronic hepatitis cause hepatocyte injury and the release of reactive oxygen species (ROS) and Kupffer cells activation. These produce proinflammatory and fibrogenic cytokines resulting in the recruitment of immune cells. The Kupffer cells also activate hepatic stellate cells which produce extracellular matrix proteins and cytokines. Repeating cycles of this activation and inflammation lead to cirrhosis characterised by regenerative nodules and irreversible fibrosis [2, 3, 5].
The ability of the virus to cause liver injury is associated with genetic changes that affect both viral and host DNA leading to mutations that predispose to liver injury and possible cancer. These events link chronic HBV infection with HCC. More than 80% of HCC cases arise in chronic HBV infection, strongly suggesting that HBV is an important contributor to the development of tumour [2, 3].
Possible mechanisms by which HBV infection causes HCC have been described, and these include HBV DNA integration, epigenetic alterations (change in gene expression) and aberrant transcriptional activities of HBx protein [3, 6, 7]. Nearly 90% of HBV-related HCC cases show evidence of HBV integration into the host genome [3, 8]. This is associated with genetic changes such as genomic instability, deletions and chromosomal translocations in the host cells, which may lead to accumulation of mutations and epigenetic changes with a malignant phenotype. Several contributing environmental and viral factors such as chronic tobacco smoking, alcohol consumption, aflatoxins, HBV e antigen positive status, high viral load and HBV genotype have been identified in HBV-related HCC cases and are associated with many epigenetic changes [3, 8–10].
1.1. Transmission Routes of HBV
HBV can be stable for 7 days or more on dry environmental surfaces. The two major routes of HBV transmission are horizontal and perinatal or vertical transmission. The efficient modes of transmission are blood and sexual contact with an infected person. The virus is horizontally transmissible during child to child physical contact or through contact with blood or infected toys. Horizontal transmission can also occur through body fluids such as semen and vaginal secretions. Perinatal or vertical transmission of HBV occurs through blood or secretions from an infected mother to the newborn baby during delivery. Perinatal transmission is high in mothers who are positive for hepatitis B e antigen (HBeAg) at 85–90% and lower in those who are negative for HBeAg where the rate is 5–20% [1, 3, 11–13].
1.2. Global epidemic of HBV infection
Worldwide, it is estimated that more than 400 million people are currently living with chronic HBV infection, contributing to more than one million deaths annually . The prevalence of HBV infection is determined by the seroprevalence of HBsAg. HBV is highly endemic in Asia and sub-Saharan Africa with HBsAg seroprevalence rates exceeding 8% (Figure 1) [3, 14]. In these regions, the infection is typically acquired at birth or in early childhood. Progression to chronic HBV infection is common in these regions and is associated with prevalence rates of 30% for hepatic cirrhosis and 53% for HCC .
Annually, approximately one million people are diagnosed with HCC worldwide, and more than half of these people die within a year of diagnosis. Studies show that the highest HCC incidence rates of 70–80% occur in South-East Asia and sub-Saharan Africa, the regions with a high prevalence of chronic HBV infection . This is due to various factors that include the late presentation of patients with large tumours, failure to recognise those at risk, high prevalence of risk factors in the population, lack of medical facilities for early diagnosis and limited access to effective treatment after diagnosis [3, 16].
An intermediate HBsAg seroprevalence of 2–7% is seen in some parts of Asia, Europe, America and Russia. The prevalence of HBV infection is low in Western Europe, Australia and United States where HBsAg seroprevalence is <2% [3, 17].
1.3. Epidemic of HBV infection in Africa
There are 65 million individuals infected with chronic HBV in Africa and 250,000 of these people die annually due to HBV-related diseases. The prevalence of chronic HBV infection in Africa varies by geographic region. It is high in sub-Saharan Africa, with HBsAg seroprevalence rates of more than 8%. In Kenya, Sierra Leone, Zambia, Senegal and Liberia, the prevalence of HBV infection is intermediate with HBsAg seroprevalence rates ranging from 2 to 8%. North African countries including Morocco, Egypt, Algeria and Tunisia have low prevalence rates of <2%.
In South Africa and other African countries, the prevalence of HBV infection is much higher in rural compared to urban areas . Low socio-economic status, infected household contact, unsafe sexual intercourse, sharing of partially eaten sweets or chewing gum, dental work and bathing towels may be some of the contributing factors for the high prevalence of HBV infection in rural areas [3, 12, 18].
1.4. HBV genotypes and genomic alterations
HBV is classified into eight genotypes (A–J) with four major serotypes (adw, adr, ayw and ayr) [3, 19, 20]. HBV genotypes are differentiated by more than 8% sequence divergence in the entire genome and more than 4% at the level of S gene. They have distinct geographical distribution as illustrated in Table 1. Genotype A is predominant in sub-Saharan Africa, North-West Europe and North America.
|Genotype||Geographic distribution||Mutation||Host CpG promoter methylation|
|North America, Sub-Saharan Africa, North-West Europe||G1888A 1762T1764A G1862T||Induces hypomethylation and down-regulation of the |
|Indonesia, China, Vietnam||Unknown||Unknown|
|East Asia, Korea, China, Japan, Polynesia, Vietnam||Unknown||Unknown|
|Mediterranean area, Middle East||G1896A||Induces hypermethylation and down-regulation of |
|Central and South America, Polynesia||Unknown||Unknown|
|Mediterranean area, Middle East||Unknown||Unknown|
Genotype A has four subgenotypes. Subgenotype 1A is common in South Africa, Malawi, Tanzania, Uganda, Somalia, Yemen, India, Nepal, Brazil and the Philippines [3, 20]. There are three CpG islands within HBV genotype A, which are associated with methylation of the promoter of
Genotypes B and C are more prevalent in Asia, Indonesia and Vietnam . Based on the phylogenetic analysis, it was demonstrated that HBV genotype C is subdivided into 5 subgenotypes (C1–C5). Geographical clustering of these subgenotypes was clear. The subgenotype C1 was found to be prevalent in East Asia, subgenotype C2 in South-East Asia, subgenotypes C3 and C4 in Southern Pacific Ocean and subgenotype C5 in Philippines [3, 22–34]. Genotype D is commonly found in the Mediterranean region and Middle East. The hepatitis B x (HBx) protein is associated with hypermethylation and down-regulation of the
HBV has a mutation rate of 10%, which is relatively high compared to other viruses. It replicates via reverse transcription of RNA intermediates that result in random mismatched base errors during genomic replication. HBV DNA polymerase lacks the ability to proofread these errors, and this predisposes HBV to mutations [3, 25]. HBV develops four major mutations which are the precore, basic core promoter, tyrosine-methionine-aspartate-aspartate (YMDD) and asparagines-to-threonine (rtN236T) mutations. The precore mutants were the first to be identified and are characterised by a nonsense G1896A mutation [3, 26]. The G1896A mutation is responsible for HBeAg negativity in chronic HBV carriers and induces the down-regulation of HLA class II molecules in hepatocytes. This mutation is common in individuals infected with HBV genotype D [3, 27]. The basic core promoter mutations include A1762T and G1764A and were identified after the precore mutations. Similar to the precore mutations, the basic core promoter mutations are found in HBeAg-negative individuals where they prevent HBeAg expression [3, 28].
1.5. Prevention and treatment
HBV infection can be prevented by avoiding direct contact with any HBV-contaminated fluids and materials. Immunisation with recombinant hepatitis B vaccines is recommended for all infants at birth and in individuals who are at high risk of acquiring the infection. Passive immunoprophylaxis with hepatitis B immunoglobulin derived from sera of positive HBV individuals is used to prevent mother-to-child HBV transmission at birth, after liver transplantation for HBV infection, needle-stick injuries and sexual intercourse [3, 20, 29].
Acute HBV infection does not require treatment as it usually resolves spontaneously. Two major classes of drugs available for treating chronic HBV infection include the injectable standard interferon-α and pegylated interferon-α2, and the oral nucleos(t)ide analogues. Nucleoside analogues are lamivudine, entecavir, telbivudine, whilst nucleotide analoques are adefovirdipivoxil and tenofovir. The main aims of treatment are to improve long-term survival by reducing the risk of developing cirrhosis and HCC [3, 30, 31].
Treatment with oral nucleos(t)ide analogues is associated with the development of mutations. Lamivudine induces point mutations in the YMDD motif of the HBV polymerase, and these include rtM204V and rtM204I mutations. The viral replication rate increases in the presence of lamivudine resistance, and when lamivudine treatment is stopped, the wild-type virus reestablishes itself. Lamuvidine resistance mutations are responsible for the development of resistance in entecavir that is also associated with similar mutations and more including rtI169T, rtT184G, rtS202I and rtM250V [3, 32, 33]. Telbivudine has a high antiviral potency and relatively low resistance than lamuvidine and entecavir. It is associated with mutations at rtL80I/V, rtL180M, rtA181T/V, rtM204I and rtL229W/V. Telbivudine results in myoparthy and neuropathy when used simultaneously with pegylated interferon-α2, and therefore, combination of these two agents is avoided [3, 32, 34].
Adevovir treatment causes mutations that are associated with the emergence of resistant strains such as the rtN236T mutation which is downstream to the YMDD motif . The use of adevovir treatment is now rare as it is associated with severe kidney injury, which may be a consequence of mitochondrial DNA depletion and activity of multidrug resistance-associated protein 4 [3, 36].
Despite the availability of treatment for chronic HBV infection, many patients will develop cancer, and this remains a major medical problem worldwide. This may be attributed to HCC-associated risk factors such as the HBV genotype, alanine aminotransferase (ALT), HBV load and HBV surface antigen level, which may influence the response to chronic HBV treatment. The response to interferon is significantly higher in patients infected with HBV genotype A compared to D and in patients with lower levels of HBV DNA and higher levels of ALT [3, 37, 38].
Aberrant methylation of promoter CpG islands is the primary epigenetic change seen during the course of HBV infection as it progresses to cirrhosis and HCC. Such methylation is detected at higher rates in HCC tissues compared to liver cirrhosis without cancer . In a recent large cohort study report by Tseng et al., high HBV surface antigen levels are associated with a risk of developing HCC even in the presence of low HBV DNA levels. This finding may be due to a higher degree of viral HBV surface antigen integration into the host genome that would result in mutations and epigenetic alteration particularly DNA methylation, causing chronic liver damage, malignant transformation and HCC [3, 38–40].
The association of DNA methylation with chronic HBV treatment was first observed during telbivudine treatment. Telbivudine is a thymidine agent that interacts with protein kinases to form telbivudine 5′–triphosphate via phosphorylation. Telbivudine 5′–triphosphate competes with thymidine 5′–triphosphate, leading to the suppression of HBV DNA polymerase and reduced viral replication. Interestingly, telbivudine was recently reported to correct HBV-induced histone methylation in HBV-infected hepatocytes [3, 41].
1.6. Virological characteristics of HBV
HBV virions are infectious double-shelled particles of approximately 40–42 nanometre (nm) in diameter. They consist of a nucleocapsid core of 27 nm in diameter, which forms the inner part of enveloped virions known as Dane particles. The nucleocapsid core is surrounded by an outer surface antigen coat of ~4 nm thickness. It contains HBsAg and hepatitis B core antigen (HBcAg), which are detected in the sera of HBV-infected individuals in the form of spherical and filamentous particles [1, 3, 19, 42].
HBV is classified as an
The HBV genome contains four ORFs, which have the same orientation and partially overlap. These ORFs encode the viral envelope pre-S/S, a pre-core/core, a polymerase and X proteins. The viral envelope also encodes three surface glycoproteins, which are the large (L), middle (M) and small (S) glycoproteins (Figure 2). These surface glycoproteins are synthesised by the initial transcription of pre-S/S. The L surface glycoprotein is important for viral assembly and infectivity, whilst the function of M surface glycoprotein is unknown. The longest open reading frame encodes the viral polymerase which serves as a reverse transcriptase and DNA polymerase. The pre-S/S envelope open reading frame overlaps the precore/core and X open reading frames and encodes HBsAg. The precore/core open reading frame produces HBeAg and HBcAg through cleavage by cellular proteases. HBcAg is the nucleocapsid and encloses the viral DNA [3, 11, 42, 43].
HBx protein is a transactivating protein that alters the expression of some genes via DNA methylation leading to tumourigenesis. It consists of 154 amino acid residues with a molecular weight of 27 kDa and is encoded by the smallest ORF. It stimulates viral replication either by activating viral transcription or by enhancing the reverse transcription of the viral polymerase [44, 45]. In hepatoma cell lines, HBx protein enhances viral replication by interacting with DNA binding protein 1 which interferes with cell growth and viability. In mice infected with wild-type HBV, viral replication is stimulated by HBx protein, suggesting that HBx protein is required for viral replication in normal hepatocyte cells [3, 44, 46, 47].
1.7. Life cycle of HBV
Due to the lack of efficient in vitro infection systems and animal models in which to study the life cycle of HBV infection, a lot of data are from the duck model infected with duck hepatitis B virus (DHBV) [3, 48]. HBV life cycle begins through the interaction of HBsAg with cellular receptor/s at the surface of hepatocytes. A number of potential cellular receptors that interact with HBsAg during HBV infection have been previously identified, but the mechanisms of action still remain controversial as none of them has been proved to be functional to HBV. These receptors include retinoid X receptor (RXR), peroxisome proliferator-activated receptor (PPAR) and farnesoid X receptor (FXR) [3, 49, 50].
Sodium taurocholate cotransporting polypeptide (NTCP) was discovered as the potential receptor for HBV infection (Figure 2). NTCP is abundantly expressed in the liver and is involved in the transportation and clearance of bile acids from portal blood into hepatocytes. Yan et al.  have shown by using near-zero-distance photo-cross-linking, tandem affinity purification and mass spectrophotometry that the pre-S/S envelope domain, a key determinant for receptor/s binding, selectively interacts with NTCP to facilitate HBV infection. Knockdown of the NTCP expression in duck primary hepatocytes infected with DHBV significantly decreased HBV infection, suggesting that NTCP is actually required for HBV infection [3, 51, 52].
HBV requires DNA polymerase and reverse transcriptase to replicate through RNA intermediates known as pregenomic RNA. Following the interaction of surface antigen with NTCP, the viral nucleocapsid enters the host cell’s nucleus to deliver dsDNA (Figure 3) [3, 51, 52]. In the nucleus, the dsDNA gets repaired and converted to covalently closed circular super-coiled DNA (cccDNA) by DNA polymerase. The cccDNA molecule serves as a template for the transcription of four viral RNA transcripts 3.5, 2.4, 2.1 and 0.4 kb in size, pregenomic RNA and RNA intermediate for viral replication before moving to the cytoplasm. The mRNA transcripts are then translated to produce the envelope (pre-S/S), precore/core, viral polymerase and X proteins. The 3.5 RNA transcript is reverse-transcribed into viral dsDNA [3, 8, 11, 40, 48, 53]. Some of the resulting viral DNA and polymerase-containing capsids are enveloped via budding into the endoplasmic reticulum (ER). The rest of the viral DNA is recycled or is migrated back to the nucleus where it produces new generations of cccDNA which maintains persistent HBV infection [1, 3, 11, 36, 40].
2. Epigenetics and HBV-induced hepatocarcinogenesis
Epigenetics involves attachment of chemical compounds and proteins on the DNA sequence leading to altered gene expression and normal function. There are two major ways through which gene transcription can be regulated through epigenetic changes. One way of regulating gene transcription is directly through DNA methylation. This involves the addition of a methyl group into DNA sequence. Methyl groups are carbon and hydrogen molecules which bind to the genome through the action of methyl cytosine-phosphate-guanine (CpG)-binding proteins (MeCPs), DNA methyltransferases (DNMTs), histone acetyltransferases (HATs) and histone deacetylases (HDACs), which inactivate gene transcription. Other transcription repressors including nuclear factor kappa B (NF-κB), c-myc/c-myn, activator protein (AP)-2, E2 promoter binding factor (E2F) and cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) may also be activated by methyl groups to inhibit gene transcription [3, 53, 54].
In addition to DNA methylation, epigenetics can also be regulated by histone protein modifications. Histone protein modifications may be caused by over-expression or aberrant recruitment of HDACs that remodel the chromatin shape and structure. The two basic mechanisms responsible for chromatin remodelling are histone acetylation and deacetylation [3, 53, 55]. These mechanisms are controlled by the enzyme activity of HATs and HDACs, respectively [3, 54].
Acetylation of histone proteins is generally acknowledged as playing a key role in gene regulation. For a gene to be transcribed, it must become physically accessible to the transcriptional machinery. Acetylation by HATs substitutes the positive charges on the amino terminal tails of histone proteins with an acetyl group derived from acetyl coenzyme A, causing uncoiling of the DNA and euchromatin into an open-relaxed form of chromatin. Consequently, this makes genes accessible to several binding factors such as RNA polymerase II and transcriptional factors, allowing gene expression to occur and proteins to be made. Deacetylation of histone proteins by HDACs results in the tight coiling of the DNA and closed form of chromatin regions known as heterochromatin. This prevents the interaction between DNA and transcription factors leading to suppression of gene transcription. In some cancer cells, there is increased expression or aberrant recruitment of HDACs and decreased expression of HATs. This results in the hypoacetylation of histone proteins and therefore a condensed or closed chromatin structure [3, 54–56].
Epigenetics plays important roles in oncogenic viruses including HBV, human papillomavirus and Epstein Barr virus. In episomal HBV DNA, 3 CpG islands have been identified and described. These are island 1 located on nucleotide positions 55–286, island 2 on 1224–1667 and island 3 on 2257–2443 . Methylation of CpG islands in the human genome is known to regulate gene transcription. These prompted Vivekanandan et al.  to hypothesise that methylation of CpG islands in HBV DNA may regulate viral gene expression. To test this hypothesis, in vitro methylation of the transfected HBV DNA was done, and this resulted in decreased expression of HBV mRNA and proteins in the cells. In addition, the effect of viral cccDNA methylation in the liver tissue of patients with chronic HBV infection was investigated and found to be associated with reduced HBV replication . These findings support the work of Pollicino et al. [3, 58] who showed that HBV replication is regulated by the acetylation of HBV cccDNA bound H3 and H4 histone proteins. Although these data suggest that HBV DNA methylation is a novel mechanism that influences the regulation of viral gene expression, the mechanisms of action are still not known.
Previous human studies have shown that DNA viruses integrate into the host genome and that the expression levels of DNMTs increase in response to active viral replication . Vivekanandan et al.  hypothesised that the up-regulation of DNMTs gives infected cells the ability to methylate viral DNA and therefore control viral replication. To investigate this, the expression of DNMTs was measured in cell lines exposed to HBV DNA using two experimental systems, one of temporary transfection of cells and another that mimicked natural chronic infection. High-level expressions of DNMT 1, 2 and 3 were observed in response to persistent HBV infection. This correlated with suppressed viral replication associated with methylation of HBV DNA and increased methylation of host CpG islands [3, 58].
The seminal work of Vivekanandan et al.  allows for the development of a model that explains the development of liver injury and HCC in chronic HBV infection (Figure 4). In this model, infected host cells respond to HBV infection by up-regulating the expression of DNMTs. Up-regulation of DNMTs can also result from interaction with HBx transcriptional activator protein. Once activated, DNMTs methylate HBV DNA and switch off the expression of viral mRNA and proteins, thereby reducing viral replication. The methylation of integrated HBV DNA may be detrimental to the host genome through the inappropriate methylation of the neighbouring host genome, particularly if the promoter CpG islands regions of the gene are affected. A consequence of this effect would be the transcriptional repression of host immunoregulatory and tumour suppressor genes that prevent the development of cancer [3, 58].
HBV integrates into the host genome and promotes viral persistence. Infected cells increase the expression of DNMTs in response to viral replication. This causes methylation of HBV cccDNA and reduces viral replication. The same methylation system methylates the adjacent host tumour suppressor and immunoregulatory genes leading to hepatocarcinogenesis.
2.1. Integration of HBV DNA into the human genome
HBV integration was first discovered in 1980 using Southern blot hybridisation. It was associated with genomic instability such as loss of heterozygocity (LOH), resulting in the rearrangements, deletions, duplications and inversions of the host and viral genomic sequences. Viral integration results in the insertion of HBV DNA sequences such as HBx gene in the host genome and enables viral persistence [3, 7, 8].
Integration of HBV in the host genome also occurs in woodchucks and other animal models. In woodchucks and California ground squirrels (Spermophilusbeecheyi), HBV genome integrates close to
The occurrence of integrated HBV DNA at preferential sites in the human chromosomes has been identified using Alu-PCR-based technique. The preferential sites are known as chromosomal fragile sites (CFS) and are non-random [3, 8]. HBV DNA integrates into the human genome soon after the repair and conversion of HBV DNA to cccDNA [3, 57, 58, 62]. The HBV genome integrates within the coding sequence or close to an array of key regulatory cellular genes that can deregulate proto-oncogenes and tumour suppressor genes. Activation or inactivation of such genes promotes genomic chromosomal instability by altering various cellular signalling pathways, triggering genetic mutations and epigenetic alteration. Mutagenesis and epigenetic alteration result in the abnormal regulation of the targeted genes. This promotes malignant transformation by altering the control of cell growth, differentiation, proliferation and apoptosis [3, 57, 58, 63]. The integration of HBV at or within
|Chromosomal fragile sites||Target gene||Role in tumour development|
|FRA1A (1p36)||TCEA; RAR; CHML||Alters gene expression and promote cell survival|
|FRA2C (1q)||EMX2-like gene||Modulates β-catenin signalling pathway and cell survival|
|FRA4E (4p)||Cyclin A||Stimulate cell cycle and anti-apoptotic effect|
|FRA3D (3q25.3)||IRAK2||Promotes apoptosis and tumour progression|
|FRA5C (5p31.1)||PDGFRβ||Regulates DNA synthesis and fibrotic genes|
|FRA7 (7p)||SERCA 1; NCF1||β-Catenin activation|
|FRA9 (9q)||KLF1; CASPR3||Promote cell growth; regulates DNA methylation|
|FRA10A (10q)||PTEN; PI3K||Promotes metastasis; promotes cell cycle progression|
|FRA11A (11q13)||EMS1, FGF4; BIRC3||Modulates β-catenin signaling pathway; alters cell fate|
|FRA12A (12q24)||ErbB3; Mill2||Promotes tumour progression|
|FRA13A (13q32)||CTGF; CCNL; IMP-2||Tumour suppression|
|FRA18 (18q)||DCC; DPC4||Regulates methyl-CpG-binding proteins|
|FRA19A (19q13)||Cyclin E||Delays DNA synthesis and promotes immortalisation|
|FRA20 (20P12.3)||hTERT||Alters gene expression and promotes cell survival|
2.2. HBx protein and its carcinogenic effects
HBx protein is a transcriptional transactivator that HBV uses to integrate into the host cellular DNA and is associated with malignant transformation in hepatocytes. It interacts with nuclear transcription factors such as NF-κB, AP1, CREB, TATA-binding protein (TBP), peroxisome proliferator-activated receptor γ (PPARγ) and transcription factor II H (TFIIH) . Interaction of HBx protein with these transcription factors disrupts multiple cellular signalling pathways that include janus kinase 1 (JAK1)-signal transducer activator of transcription (STAT), mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) and p53 signalling pathways. Cellular signalling pathways are important in regulating DNA repair, cell growth, differentiation, adhesion, proliferation and apoptosis. Although the precise mechanisms of action are still being elucidated, HBx protein has also been shown to induce methylation of important tumour suppressor genes critical in HBV-induced hepatocarcinogenesis by modulating DNMTs [3, 44, 45, 47, 63, 65, 66].
The transcriptional transactivation role of HBx protein on the transforming growth factor beta 1 (TGF-β1) protein may be important in explaining liver inflammation and fibrosis. TGF-β1, encoded by
Studies show that in HBx transgenic mice and hepatoma cell lines, HBx protein can transactivate the NF-κB, MAPK/ERK, STAT3 and PI3K/Akt cellular signalling pathways by inducing the production of ROS. Accumulation of ROS in human cancers is associated with anti-apoptotic activity, DNA damage and mutations which promote malignant transformation. HBx-induced ROS and 8-oxoguanine alter the expression of PTEN protein by oxidising cysteine residues within the promoter region encoding
2.3. HBx protein and DNA methylation
HBx protein has been labelled an epigenetic deregulating agent. It uses its oncogenic ability to induce promoter methylation of some cellular tumour suppressor genes that contribute to the development of liver cancer [3, 73]. Cancer-associated DNA methylation may be global hypomethylation (less methylation) or hypermethylation (increased methylation). Abnormal hypermethylation of various cellular genes including host tumour suppressors has been described in liver cancer, and it is associated with silencing of genes critical for preventing malignant transformation [3, 56]. Altered gene expression has been reported in HBV infection where the DNA methylation machinery is induced as a host defence mechanism to suppress viral genes [3, 53, 57, 58]. This correlates with loss of normal activity in genes important for wound healing and immune processes. Disruption of these processes will interfere with normal cell proliferation and apoptosis and potentiates the ability to metastasize in abnormal cells as seen in chronic liver disease and malignant transformation [3, 58, 63]. By modulating the transcriptional activation of DNMTs, HBx protein induces the hypermethylation of tumour suppressor gene promoters and silences their expression [3, 74–77].
HBx protein induces the hypermethylation of
Caveolin-1, encoded by c
HBx-protein-induced DNA hypermethylation has also been connected with loss of expression and normal function of
Genome-wide studies aided in identifying DNA methylation, histone modifications and miRNA expression profiling across the entire samples with CHB and HBV-related HCC [3, 84–86]. Preliminary data conducted by Kgatle et al.  demonstrate that HBV-induced methylation may affect cellular processes such as cell cycle progression, calcium homeostasis, hepatic metabolism, protein ubiquitination, RNA splicing and vitamin D receptor regulation, which are key mechanisms that HBx protein alters to favour viral replication and cell survival. Disruption in these cellular processes could cause genetic instability, hepatocyte transformation and tumour development. However, amongst most conducted genome-wide studies, there are some discrepancies and data variations due to lack of proper normal control, heterogeneity of disease, variations of samples source, use of different technologies for analysis and validation with gene expression analysis, suggesting need for further validations [3, 84].
Substantial data show that there is an association between the methylation of CpG islands and transcriptional changes in gene promoter regions. Transcriptional alterations within gene promoter regions interfere with the normal function of a wide spectrum of cellular genes including tumour suppressor genes which are potential inducers of malignancies. Oncogenic viruses integrate themselves into the human genome and alter gene transcription through DNA methylation. During HBV infection, the expression levels of DNMTs are elevated in response to viral replication as viral genes are methylated to suppress viral replication. This may result in inappropriate random methylation of neighbouring host cellular genes, including tumour suppressor genes. This would cause malignant transformation and ultimately liver cancer. In addition, other genes affected by methylation may contribute to the development of liver inflammation, fibrosis and cirrhosis. As a multifunctional viral transactivator, the HBx protein may be the driving force behind the activation of DNMTs, causing gene promoter hypermethylation and gene silencing. The epigenetic alteration of genes may affect cellular signalling pathways and favour uncontrolled hepatocyte proliferation and HBV-induced inflammation, fibrosis and cancer.
Liaw Y, Chu C: Hepatitis B virus infection. Lancet 2009, 373: 582–592.
Beasley RP: Rocks along the road to the control of HBV and HCC. Ann. Epidemiol. 2009, 19: 231–234.
Kgatle MM: An investigation of genome-wide promoter region cytosine-phosphate-guanine (CpG) Island methylation profiles in patients with chronic hepatitis B virus infection. University of Cape Town Thesis; 2014: 19–43.
Blumberg BS, Gerstley BJS, Hungerford DA, London WT, Sutnick AI: A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann. Intern. Med. 1967, 66: 924–931.
Fausto N, Campbell JS, Riehle KJ: Liver regeneration. Hepatology 2006, 43.
Brechot C, Pourcel C, Louise A, Rain B, Tiollais P: Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma 1980.
Sung W, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C: Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 2012, 44: 765–769.
Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Brechot C, Paterlini-Brechot P: Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005, 54: 1162–1168.
Popescu NC, Zimonjic D, DiPaolo JA: Viral integration, fragile sites, and proto-oncogenes in human neoplasia. Hum. Genet. 1990, 84: 383–386.
Yang H, Lu S, Liaw Y, You S, Sun C, Wang L, Hsiao CK, Chen P, Chen D, Chen C: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 2002, 347: 168–174.
Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP: Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 2006, 28: 112–125.
Karayiannis P, Novick DM, Lok AS, Fowler MJ, Monjardino J, Thomas HC: Hepatitis B virus DNA in saliva, urine, and seminal fluid of carriers of hepatitis B e antigen. Br. Med. J. (Clin. Res. Ed) 1985, 290: 1853–1855.
Zonneveld M, Nunen A, Niesters H, Man R, Schalm S, Janssen H: Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J. Viral Hepat. 2003, 10: 294–297.
Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004, 11: 97–107.
Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127: S35–S50.
Bréchot C: Pathogenesis of hepatitis B virus—related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004, 127: S56–S61.
Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, Bell B: The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J. Infect. Dis. 2010, 202: 192–201.
Kramvis A, Kew MC: Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol. Res. 2007, 37.
Glebe D: Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J. Gastroentrol. 2007, 13: 14–21.
Lin C, Kao J: The clinical implications of hepatitis B virus genotype: recent advances. J. Gastroenterol. Hepatol. 2011, 26: 123–130.
Qiu G, Salto-Tellez M, Ross JA, Yeo W, Cui Y, Wheelhouse N, Chen GG, Harrison D, Lai P, Tao Q: The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. J. Hepatol. 2008, 48: 433–441.
Kramvis A, Arakawa K, Yu MC, Nogueira R, Stram DO, Kew MC: Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus. J. Med. Virol. 2008, 80: 27–46.
Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO: Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004, 47: 289–309.
Sakamoto T, Tanaka Y, Orito E, Clavio J, Sugauchi F, Ito K, Ozasa A, Quino A, Ueda R, Sollano J: Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. J. Gen. Virol. 2006, 87: 1873–1882.
Echevarría JM, Avellón A: Hepatitis B virus genetic diversity. J. Med. Virol. 2006, 78: S36–S42.
Min XC, Miao XH, Zhao SM, Zhao KK, Yang DG: The spontaneous YMDD mutation rate in chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2009, 17: 887–890.
Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, et al.: Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl. Cancer Inst. 2008, 100: 1134–1143.
Fang Z, Sabin CA, Dong B, Wei S, Chen Q, Fang K, Yang J, Wang X, Harrison TJ: The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis. J. Hepatol. 2009, 50: 273–280.
Kao JH, Chen PJ, Lai MY, Chen DS: Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J. Clin. Microbiol. 2002, 40: 1207–1209.
Shaw T, Locarnini S: Entecavir for the treatment of chronic hepatitis B. Expert review of anti-infective therapy 2014.
Trépo C, Chan HL, Lok A: Hepatitis B virus infection. Lancet 2014, 384: 2053–2063.
Perrillo R, Hann H, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E: Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004, 126: 81–90.
Chon CY, Han K, Ahn SH: Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir. Ther. (Lond.) 2010, 15: 235–241.
Han G, Cao M, Zhao W, Jiang H, Wang C, Bai S, Yue X, Wang G, Tang X, Fang Z: A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J. Hepatol. 2011, 55: 1215–1221.
Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO, et al.: Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006, 55: 1488–1495.
Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS: Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol. 2008, 48: 391–398.
Kao J, Chen P, Chen D: Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv. Cancer Res. 2010, 108.
Tseng T, Liu C, Yang H, Su T, Wang C, Chen C, Kuo SF, Liu C, Chen P, Chen D: High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012, 142: 1140–1149. e3.
Zeng L, Lian J, Chen J, Jia H, Zhang Y, Xiang D, Yu L, Hu J, Lu Y, Zheng L: Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study. World J. Gastroenterol. 2014, 20: 9178–9184.
Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA: Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J. Hepatol. 2010, 52: 508–513.
Tian Y, Ni D, Yang W, Zhang Y, Zhao K, Song J, Mao Q, Tian Z, van Velkinburgh JC, Yang D: Telbivudine treatment corrects HBV-induced epigenetic alterations in liver cells of patients with chronic hepatitis B. Carcinogenesis 2014, 35: 53–61.
Ganem D, Prince AM: Hepatitis B virus infection—natural history and clinical consequences. N. Engl. J. Med. 2004, 350: 1118–1129.
Scaglioni PP, Melegari M, Wands JR: Recent advances in the molecular biology of hepatitis B virus. Baillière's Clin. Gastroenterol. 1996, 10: 207–225.
Murakami S: Hepatitis B virus X protein: a multifunctional viral regulator. J. Gastroenterol. 2001, 36: 651–660.
Park IY, Sohn BH, Yu E, Suh DJ, Chung Y, Lee J, Surzycki SJ, Lee YI: Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007, 132: 1476–1494.
Chung TW, Lee YC, Kim CH: Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J. 2004, 18: 1123–1125.
Shih WL, Kuo ML, Chuang SE, Cheng AL, Doong SL: Hepatitis B virus X protein inhibits transforming growth factor-beta -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J.Biol.Chem. 2000, 275: 25858–25864.
Weiner AJ, Choo QL, Wang KS, Govindarajan S, Redeker AG, Gerin JL, Houghton M: A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J. Virol. 1988, 62: 594–599.
Dandri M, Lutgehetmann M, Volz T, Petersen J: Small animal model systems for studying hepatitis B virus replication and pathogenesis 2006, 26: 181–191.
Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 1995, 83: 841–850.
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, et al.: Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012, 1: e00049.
Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, Li W: Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J.Virol. 2014, 88: 3273–3284.
Esteller M: Epigenetics in cancer. N.Engl.J.Med. 2008, 358: 1148–1159.
Holliday R: Epigenetics: a historical overview. Epigenetics 2006, 1: 76–80.
Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 1997, 389: 349–352.
Bestor TH, Chandler VL, Feinberg AP: Epigenetic effects in eukaryotic gene expression. Dev. Genet. 1994, 15: 458–462.
Vivekanandan P, Thomas D, Torbenson M: Hepatitis B viral DNA is methylated in liver tissues. J. Viral Hepat. 2008, 15: 103–107.
Vivekanandan P, Thomas D, Torbenson M: Methylation regulates hepatitis B viral protein expression. J. Infect. Dis. 2009, 199: 1286–1291.
Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M: Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006, 130: 823–837.
Wang Y, Lau SH, Sham JS, Wu M, Wang T, Guan X: Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis. Oncogene 2004, 23: 142–148.
Jacob JR, Sterczer A, Toshkov IA, Yeager AE, Korba BE, Cote PJ, Buendia M, Gerin JL, Tennant BC: Integration of woodchuck hepatitis and N‐myc rearrangement determine size and histologic grade of hepatic tumors. Hepatology 2004, 39: 1008–1016.
Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC: Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma: studies in percutaneous liver biopsies and post-mortem tissue specimens. N. Engl. J. Med. 1981, 305: 1067–1073.
Lupberger J, Hildt E: Hepatitis B virus-induced oncogenesis. World J. Gastroenterol. 2007, 13: 74.
Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle H, Matsuda M, Fujii H, Scoazec J, Ohgaki H: Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int. J. Cancer 2003, 106: 334–341.
Lee Y, Yun Y: HBx protein of hepatitis B virus activates Jak1-STAT signaling. J. Biol. Chem. 1998, 273: 25510–25515.
Zhang X, Zhang H, Ye L: Effects of hepatitis B virus X protein on the development of liver cancer. J. Lab. Clin. Med. 2006, 147: 58–66.
Gressner A, Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF‐β as major players and therapeutic targets. J. Cell. Mol. Med. 2006, 10: 76–99.
Yoo YD, Ueda H, Park K, Flanders KC, Lee YI, Jay G, Kim SJ: Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J. Clin. Invest. 1996, 97: 388–395.
Lee DK, Park SH, Yi Y, Choi SG, Lee C, Parks WT, Cho H, de Caestecker MP, Shaul Y, Roberts AB, Kim SJ: The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev. 2001, 15: 455–466.
Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Tahashi Y, Mori S, Uemura Y, Sakaida N, Fujisawa J, Seki T: Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)‐β signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 2009, 49: 1203–1217.
Murata M, Thanan R, Ma N, Kawanishi S: Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. J. Biomed. Biotechnol. 2012, 2012: 623019.
Lim W, Kwon S, Cho H, Kim S, Lee S, Ryu W, Cho H: HBx targeting to mitochondria and ROS generation are necessary but insufficient for HBV-induced cyclooxygenase-2 expression. J. Mol. Med. 2010, 88: 359–369.
Zheng D, Zhang L, Cheng N, Xu X, Deng Q, Teng X, Wang K, Zhang X, Huang J, Han Z: Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J. Hepatol. 2009, 50: 377–387.
Lee J, Kwun HJ, Jung JK, Choi KH, Jang KL: Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 2005, 24: 6617–6625.
Liu J, Lian Z, Han S, Waye M, Wang H, Wu M, Wu K, Ding J, Arbuthnot P, Kew M: Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene 2006, 25: 1008–1017.
Zhao J, Wu G, Bu F, Lu B, Liang A, Cao L: Epigenetic silence of ankyrin-repeat-containing, and proline-rich region-containing protein 1 (ASPP1) and ASPP2 genes promote tumour growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 2010, 51: 142–153.
Jung JK, Arora P, Pagano JS, Jang KL: Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res. 2007, 67: 5771–5778.
Niu D, Feng H, Chen WN: DLEC1 Expression is modulated by epigenetic modifications in hepatocelluar carcinoma cells: role of HBx genotypes. Cancers 2010, 2: 1689–1704.
Tse T, Yuk E, Ko F, Chi F, Tung K, Kwok E, Chan LK, Lee W, Kin T, Ngan W: Caveolin‐1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J. Pathol. 2012, 226: 645–653.
Yan J, Lu Q, Dong J, Li X, Ma K, Cai L: Hepatitis B virus X protein suppresses caveolin-1 expression in hepatocellular carcinoma by regulating DNA methylation. BMC Cancer 2012, 12: 353.
Zhu Y, Zhu R, Fan J, Pan Q, Li H, Chen Q, Zhu H: Hepatitis B virus X protein induces hypermethylation of p16INK4A promoter via DNA methyltransferases in the early stage of HBV‐associated hepatocarcinogenesis. J.Viral Hepat. 2010, 17: 98–107.
Ferber MJ, Montoya D, Yu C, Aderca I, McGee A, Thorland EC, Nagorney D, Gostout B, Burgart L, Boix L: Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003, 22: 3813–3820.
Takai D, Yagi Y, Habib N, Sugimura T, Ushijima T: Hypomethylation of LINE1 retrotransposon in human hepatocellular carcinomas, but not in surrounding liver cirrhosis. Jpn. J. Clin. Oncol. 2000, 30: 306–309.
Kgatle MM, Spearman CW, Wayne M, Ramesar R, Kalla AA, Kandpal M, Vivekanandan P, Hairwadzi HN: Genome-wide analysis of core promoter region cytosine-phosphate-guanine islands hypermethylation profiles in chronic hepatitis B virus patients in South Africa. J. Med. Health Sci. 2016, 6.
Tao R, Li J, Xin J, Wu J, Guo J, Zhang L, Jiang L, Zhang W, Yang Z, Li L: Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One 2011, 6: e19862.
Zhao Y, Xue F, Sun J, Guo S, Zhang H, Qiu B, Geng J, Gu J, Zhou X, Wang W: Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma. Clin. Epigenet. 2014, 6: 1.